The vast majority of patients with chronic myelogeneous leukemia (CML) (495%) has a breakpoint in the M-bcr, resulting in b3-a2, b2-a3, b2-a2 or b3-a3 fusion gene transcripts and the associated p210 BCR-ABL protein. 1 In rare cases of CML, the breakpoint in BCR is located in the m-bcr, resulting in an e1-a2 or e1-a3 fusion gene transcript and associated p190 protein or in the m-bcr region, resulting in an e19-a2 fusion gene transcript and the associated p230 protein. Some unusual breakpoints have been described in CML as well, including cases with transcripts derived from fusion genes in which the breaks are located within exons and cases with transcripts in which intronic sequences are inserted. 1 Here, we present a 16-year old girl with CML who showed a new type of fusion gene transcript, containing part of BCR exon 18 linked to ABL exon 2, with insertion of 10 nucleotides from intron 1b at the joining site.
A 16-year old girl was admitted to the hospital because of fatigue, headache and visual abnormalities. Liver and spleen enlargement were found at physical examination. Laboratory investigation showed a hemoglobin of 4 mmol/l, a white blood cell count (WBC) of 399 Â 10 9 /l and a platelet count of 698 Â 10 9 /l. Morphologic evaluation of peripheral blood showed 4% basophils, 3% eosinophils, o1% monocytes, 2% lymphocytes, 5% blasts and 86% myeloid cells at different stages of maturation. The Sokal score was 1.57 (high risk) and the Euro score was 1459 (intermediate risk). Karyotyping showed 46,XX,t(9;22)(q34;q11) in all metaphases. The presence of a BCR-ABL fusion gene was confirmed with FISH (BCR/ABL ES probe set, Vysis). In addition, an accompanying deletion of a part of ABL was detected in the der(9)t(9;22) by this assay. Based on these findings, a diagnosis of CML in chronic phase was established.
Treatment was started with leucapheresis and hydroxyurea. After 2 weeks, the WBC had dropped to normal values and treatment was switched to imatinib 600 mg/day, according to the Dutch Childhood Oncology Group CML protocol (imatinib dose: 400 mg/m 2 /day). Because of thrombocytopenia, imatinib was dose-reduced to 400 mg/day at day þ 37. At day þ 56 from diagnosis the patient was in complete hematological remission. Cytogenetic analysis of the bone marrow showed 41% t(9;22)-positive metaphases. FISH analysis showed the BCR-ABL fusion in 29% of interphase cells. A major cytogenetic response was established at day þ 106 with 6% t(9;22) positive metaphases. At that time, a real-time quantitative (RQ)Fpolymerase chain reaction (PCR) analysis using the primer-probe set developed within the Europe Against Cancer program 2 was performed on the diagnostic specimen as well as the bone marrow sample taken at day þ 106. This RQ-PCR showed an unexpectedly low amplification in the diagnostic sample and could not detect BCR-ABL fusion gene transcripts in the day þ 106 bone marrow. This prompted us to analyze the BCR-ABL fusion gene transcript in more detail. Therefore, PCR analysis was performed using the BIOMED-1 primer set (primer BCR-b1-A and ABL-a3-B). 3 This resulted in a PCR product of approximately 800 bp, in contrast to the p210 positive control (BV173) showing the expected PCR product of 400 bp. The PCR product of the patient was cut out of the gel, sequenced, and the obtained sequence was aligned with the germline BCR and ABL sequences (accession numbers: BCR: U07000; ABL: U07563). This showed that the fusion gene transcript in the patient contained part of exon 18 of the BCR gene (the first 90 nucleotides, the last 20 nucleotides being deleted), an insertion of 10 nucleotides, followed by exon 2 of the ABL gene ( Figure 1 ). The breakpoint at the DNA level was analyzed by ligation-mediated PCR. 4 This showed that exon 18 of BCR was coupled to the first 423 bp of intron 1b downstream of ABL exon 2, resulting in a putative splice site (Figure 1 ).
The new in-frame e18-a2 BCR-ABL transcript is 390 base pairs larger than the e14-a2 transcript (M-Bcr) and is predicted to encode a protein 130 amino acids longer than the p210 protein.
Western blot analysis, using an ABL antibody (8E9), indeed showed the presence of a protein with a molecular mass of approximately 225 kDa (data not shown). Wild-type BCR-ABL protein (p210) was not found, which is in line with the lack of a normal BCR-ABL fusion transcript. Using a flow cytometric immunobead assay (Weerkamp et al., Haematologica 2006; 91(s1):377, abstract), BCR-ABL protein was detected as well (data not shown). It should be noted that the predicted e18-a2 BCR-ABL protein contains exactly the same ABL domains as the p210 (and p190) protein, suggesting that imatinib binding will not be affected.
Based on the identified fusion gene transcript, an exon 18 specific forward primer was designed (5 0 -AGGATGCCGTCCC GAAA-3 0 ). In combination with the EAC reverse primer and probe, this resulted in a good amplification of the e18-intron 1b-a2 fusion gene transcript. MRD analysis of the day þ 106 bone marrow sample using this newly designed RQ-PCR showed a tumor load of 2 Â 10 À2 (Table 1) . MRD analysis of a bone marrow sample obtained at day þ 210 showed a further reduction of the tumor load to 2 Â 10
À3
. At day þ 239, the imatinib dose was escalated to 600 mg without recurrence of hematological toxicity. MRD analysis at day þ 285, day þ 377, and day þ 474 showed that the tumor load in the bone marrow remained relatively stable around a level of approximately 1 Â 10 À3 (Table 1) . Imatinib therapy will be continued and regular follow-up for the occurrence of resistance is planned.
To our knowledge, only seven CML patients in whom transcripts are derived from fusion genes in which the breaks are located within exons have been described so far. In two of these patients (a 65-year-old male and a 59-year-old male), the unusual transcript consisted of 86 base pairs of BCR exon 15 joined in frame with ABL exon 2 at nucleotide 78. 5 These transcripts could only be identified upon nested PCR approaches and it was hypothesized that they only occurred in a small subset of cells. Both patients showed mild clinical symptoms (moderate leukocytosis that did not increase with time) and an indolent clinical course. A third patient (a 49-year-old male) showed BCR-ABL transcripts in which part of BCR exon e2 was joined to part of ABL exon 1a; this patient had an aggressive clinical course. 6 A fourth patient (a 51-year-old male) showed an in-frame fusion consisting of part of BCR exon e8 spliced to ABL exon a2. 7 Finally, one patient (a 31-year-old male) was reported to have a break in BCR exon 3 and two patients (45-year-old and 56-year-old women) were reported with a break in BCR exon 8, in all three cases linked to ABL exon 2. 7, 8 Of interest, the latter three patients had an inserted sequence (15-44 nucleotides) derived from intron 1b in between BCR and ABL. 7, 8 The here presented case is of interest for various reasons. It is the first patient with a breakpoint within BCR exon 18. Secondly, in contrast to most other reported patients with breaks within exons, the BCR-ABL transcript in our patient contained an insertion of 10 nucleotides of intron 1b between BCR exon 18 and ABL exon 2. Third, it is remarkable that in contrast to the seven previously described patients, all adults, our case concerns a 16-year-old female. Finally, this case demonstrates that also a patient with the non-classical e18-a2 BCR-ABL fusion can respond to imatinib. Multiple myeloma (MM) is a very heterogeneous disease, related in part to numerous chromosomal abnormalities. 1 We and others have shown that plasma cells of patients with t(11;14)(q13;q32) (representing approximately 15% of the patients with MM 1 ) were mature, with a small nucleus, clumped chromatic and reduced cytoplasm.
2,3 Moreover, we have also described a strong association between both small mature plasma cell morphology, t(11;14) and CD20 expression. 4 Other data had previously suggested that the CD20 phenotype was associated with mature plasma cell morphology. 5 In the subset of patients with MM-expressing CD20, rituximab (anti-CD20 chimeric monoclonal antibody) could target the antigen and could have a clinical impact. Until now, only two phase II trial have been reported to determine the activity of rituximab in MM patients, with 1 patient out of 19 experiencing a partial response after therapy in the first one, 6 and no response in a cohort of 10 patients with pretreated advanced MM in the second one. 7 Nevertheless, in theses two series, patients were not selected according to the level of CD20 expression on plasma cells, and the majority of the patients were not expressing this phenotype at the time of therapy.
Thus, we conducted a prospective phase II trial of four weekly i.v. infusions of 375 mg/m 2 rituximab (Mabthéra, Roche pharmaceuticals, Neuilly, France) in patients with MM expressing CD20 on at least 33% of tumor cells. This study was approved by the Local Institutional Ethics Committee of the University of Nantes, was approved and registered by the French Agency for Health Security (Agence Française de Sécurité Sanitaire et des Produits de Santé: AFSSAPS). All patients gave written informed consent.
From July 2004 to February 2006, 14 consecutive patients: nine males and five females, median age 65 years (range ¼ 44-77 years) with either stage I MM never pre-treated (n ¼ 7) or stage III MM in relapse or refractory after a median of two lines of therapy (n ¼ 7) were treated. Immunophenotype using flow cytometry as previously described 4 revealed that all patients had CD20 positive MM with a median of 75% of the tumor cells were expressing CD20 (range ¼ 33-100%) at the onset of therapy. Rituximab was well tolerated. Responses were evaluated in each case 3 months after therapy according to Bladé criteria, 8 At the reference date of September 1, 2006, a single patient experienced a minor response, ongoing 18 months after rituximab therapy. This patient had previously relapsed 8 months after a double autologous stem cell transplantation. At the time of rituximab therapy, 100% of its plasma cells were expressing CD20; and 3 months after treatment, bone marrow examination showed 0.6% of plasma cells, none of them expressing CD20. Five patients (one with relapsed MM and four with stage I MM) experienced stable disease, ongoing for 3, 4, 4, 11 and 12 months, respectively. Three patients with stage I MM had stable disease but subsequently progressed 10, 11 and 15 months after therapy, respectively. The last five patients with relapsed MM did not respond to anti-CD20 therapy, despite partial clearance of CD20 þ plasma cells in the bone marrow in two cases. Conversely in the three latter cases, the percentage of CD20 þ plasma cells did not decrease despite rituximab therapy. Several factors have been described to explain resistance against rituximab in a variety of B-cell malignancies such as the level of CD20 expression, dissociated action of complementdependent cytotoxicity and antibody-dependant cellular cytotoxicity, 9 polymorphism in FcgammaRIIIA receptor and may be inadequate dose schedule. These mechanisms could explain the marginal activity of rituximab as single-agent in CD20 þ MM.
